Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1461 USD | +0.76% | -98.93% | -99.00% |
Apr. 19 | Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement | MT |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Financials (USD)
Sales 2022 | 25.9M | Sales 2023 | 42.81M | Capitalization | 17.99M |
---|---|---|---|---|---|
Net income 2022 | -33M | Net income 2023 | -24M | EV / Sales 2022 | 1.21 x |
Net cash position 2022 | 46.07M | Net cash position 2023 | 26.37M | EV / Sales 2023 | -0.2 x |
P/E ratio 2022 |
-2.32
x | P/E ratio 2023 |
-0.67
x | Employees | 48 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.57% |
Latest transcript on Pieris Pharmaceuticals, Inc.
1 day | +0.76% | ||
1 week | -98.93% | ||
Current month | -99.00% | ||
1 month | -99.09% | ||
3 months | -98.89% | ||
6 months | -99.29% | ||
Current year | -99.00% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 09-12-31 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 17-11-30 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 16-09-19 | |
James Geraghty
CHM | Chairman | 70 | 17-05-21 |
Michael Richman
BRD | Director/Board Member | 63 | 14-12-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 11.69 | +0.76% | 23,548 |
24-04-19 | 11.6 | -6.60% | 24,693 |
24-04-18 | 12.42 | -1.18% | 8,306 |
24-04-17 | 12.57 | -4.21% | 7,817 |
24-04-16 | 13.12 | -3.53% | 4,007 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-99.00% | 14.45M | |
+2.49% | 96.73B | |
-1.86% | 21.31B | |
-16.61% | 21.21B | |
-5.80% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |
- Stock Market
- Equities
- PIRS Stock